Eric Giannoni, Guillem Sanchez Sanchez, Isoline Verdebout, Maria Papadopoulou, Moosa Rezwani, Raya Ahmed, Kristin Ladell, Kelly L. Miners, James E. McLaren, Donald J. Fraser, David A. Price, Matthias Eberl, Swiss Pediatric Sepsis Study, Philipp K.A. Agyeman, Luregn J Schlapbach, David Vermijlen
{"title":"Sepsis shapes the human γδ TCR repertoire in an age- and pathogen-dependent manner","authors":"Eric Giannoni, Guillem Sanchez Sanchez, Isoline Verdebout, Maria Papadopoulou, Moosa Rezwani, Raya Ahmed, Kristin Ladell, Kelly L. Miners, James E. McLaren, Donald J. Fraser, David A. Price, Matthias Eberl, Swiss Pediatric Sepsis Study, Philipp K.A. Agyeman, Luregn J Schlapbach, David Vermijlen","doi":"10.1002/eji.202451190","DOIUrl":null,"url":null,"abstract":"<p>Sepsis affects 25 million children per year globally, leading to 2.9 million deaths and substantial disability in survivors. Extensive characterization of interactions between the host and bacteria in children is required to design novel preventive and therapeutic strategies tailored to this age group. Vγ9Vδ2 T cells are the first T cells generated in humans. These cells are defined by the expression of Vγ9Vδ2 T-cell receptors (TCRs, using the TRGV9 and TRDV2 gene segments), which react strongly against the prototypical bacterial phosphoantigen HMBPP. We investigated this reactivity by analyzing the TCR δ (TRD) repertoire in the blood of 76 children (0–16 years) with blood culture-proven bacterial sepsis caused by HMBPP-positive <i>Escherichia coli</i> or by HMBPP-negative <i>Staphylococcus aureus</i> or by HMBPP-negative <i>Streptococcus pneumoniae</i>. Strikingly, we found that <i>S. aureus</i>, and to a lesser extent <i>E. coli</i> but not <i>S. pneumoniae</i>, shaped the TRDV2 repertoire in young children (<2 years) but not in older children or adults. This dichotomy was due to the selective expansion of a fetal TRDV2 repertoire. Thus, young children possess fetal-derived Vγ9Vδ2 T cells that are highly responsive toward specific bacterial pathogens.</p>","PeriodicalId":165,"journal":{"name":"European Journal of Immunology","volume":"54 10","pages":""},"PeriodicalIF":4.5000,"publicationDate":"2024-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/eji.202451190","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Immunology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/eji.202451190","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Sepsis affects 25 million children per year globally, leading to 2.9 million deaths and substantial disability in survivors. Extensive characterization of interactions between the host and bacteria in children is required to design novel preventive and therapeutic strategies tailored to this age group. Vγ9Vδ2 T cells are the first T cells generated in humans. These cells are defined by the expression of Vγ9Vδ2 T-cell receptors (TCRs, using the TRGV9 and TRDV2 gene segments), which react strongly against the prototypical bacterial phosphoantigen HMBPP. We investigated this reactivity by analyzing the TCR δ (TRD) repertoire in the blood of 76 children (0–16 years) with blood culture-proven bacterial sepsis caused by HMBPP-positive Escherichia coli or by HMBPP-negative Staphylococcus aureus or by HMBPP-negative Streptococcus pneumoniae. Strikingly, we found that S. aureus, and to a lesser extent E. coli but not S. pneumoniae, shaped the TRDV2 repertoire in young children (<2 years) but not in older children or adults. This dichotomy was due to the selective expansion of a fetal TRDV2 repertoire. Thus, young children possess fetal-derived Vγ9Vδ2 T cells that are highly responsive toward specific bacterial pathogens.
期刊介绍:
The European Journal of Immunology (EJI) is an official journal of EFIS. Established in 1971, EJI continues to serve the needs of the global immunology community covering basic, translational and clinical research, ranging from adaptive and innate immunity through to vaccines and immunotherapy, cancer, autoimmunity, allergy and more. Mechanistic insights and thought-provoking immunological findings are of interest, as are studies using the latest omics technologies. We offer fast track review for competitive situations, including recently scooped papers, format free submission, transparent and fair peer review and more as detailed in our policies.